CN114224957A - Composition with effect of inhibiting uric acid generation and preparation method thereof - Google Patents
Composition with effect of inhibiting uric acid generation and preparation method thereof Download PDFInfo
- Publication number
- CN114224957A CN114224957A CN202111646938.7A CN202111646938A CN114224957A CN 114224957 A CN114224957 A CN 114224957A CN 202111646938 A CN202111646938 A CN 202111646938A CN 114224957 A CN114224957 A CN 114224957A
- Authority
- CN
- China
- Prior art keywords
- weight
- uric acid
- preparation
- extract
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims description 48
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims description 43
- 229940116269 uric acid Drugs 0.000 title claims description 43
- 230000000694 effects Effects 0.000 title description 11
- 230000002401 inhibitory effect Effects 0.000 title description 10
- 239000000284 extract Substances 0.000 claims abstract description 72
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 30
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims abstract description 9
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 9
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 241001018563 Nekemias grossedentata Species 0.000 claims description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 240000002878 Prunus cerasus Species 0.000 claims description 22
- 235000005805 Prunus cerasus Nutrition 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000002562 thickening agent Substances 0.000 claims description 17
- 240000002547 Rosa roxburghii Species 0.000 claims description 15
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229920002148 Gellan gum Polymers 0.000 claims description 6
- 239000000216 gellan gum Substances 0.000 claims description 6
- 235000010492 gellan gum Nutrition 0.000 claims description 6
- 239000012669 liquid formulation Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000007938 effervescent tablet Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 abstract description 22
- 239000000243 solution Substances 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 12
- 235000009226 Prunus puddum Nutrition 0.000 description 12
- 241000220317 Rosa Species 0.000 description 12
- 108010093894 Xanthine oxidase Proteins 0.000 description 12
- 102100033220 Xanthine oxidase Human genes 0.000 description 12
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 235000011371 Brassica hirta Nutrition 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241000221775 Hypocreales Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000973598 Oxyjulis californica Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a uric acid-reducing composition, which comprises 1.5-2.5 parts by weight of vine tea extract and 0.5-1.5 parts by weight of cordyceps militaris extract, wherein the vine tea extract contains 30-90% by weight of dihydromyricetin, the cordyceps militaris extract contains 0.1-0.5% by weight of cordycepin, the% by weight and the parts by weight are calculated by dry weight, and the extract is obtained by taking water as an extraction solvent.
Description
Technical Field
The invention relates to the technical field of medicines and foods, in particular to a composition for reducing uric acid.
Background
Hyperuricemia (HUA) is a metabolic disease caused by increased uric acid production and/or decreased uric acid excretion due to disturbance of purine metabolism in the body. The diagnosis of hyperuricemia is internationally defined as: under normal purine diet state, the fasting blood uric acid level is not 2 times on the same day, male is more than 420 mu mol/L, female is more than 360 mu mol/L. The latest edition of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout (2019) defines: blood uric acid levels in excess of 420 μmol/L2 times a day are known as hyperuricemia, whether in men or women.
Ampelopsis grossedentata (Hand-Mazz) W.T.Wang) tender leaves, originally recorded in tea Jing, are perennial woody vine plants of the genus Ampelopsis of the family Vitaceae. The vine tea can be used as a medicine or an edible tea, and the use of the tender stem leaves of the vine tea in tea has been known for hundreds of years. According to the records of the literature such as Chinese herbal medicine compilation, the vine tea has the efficacy of clearing heat and removing toxicity when used as a medicine, and can treat cold, wind heat, sore throat and the like. Modern researches show that the vine tea and the extractive thereof contain abundant flavonoid compounds, particularly have the highest content of dihydromyricetin, and have various pharmacological activities of resisting inflammation, resisting bacteria, resisting oxidation, reducing blood sugar, reducing blood fat, reducing blood pressure and the like.
The cordyceps sinensis is a rare Chinese herbal medicine and has high medicinal value, but the natural resource of the cordyceps sinensis is scarce, the price is high, and the cordyceps sinensis is difficult to cultivate. Cordyceps militaris (Cordyceps militaris), also known as Cordyceps militaris, belongs to Ascomycota, Hypocreales, Clavicipitaceae. The cordyceps militaris and the cordyceps sinensis belong to the same genus and different species, artificial culture and scale production are realized, and researches show that the bioactive components of the cordyceps militaris and the cordyceps sinensis are similar, so that the cordyceps militaris can be used as an effective substitute product of the cordyceps sinensis. Research shows that the cordyceps militaris is rich in various nutritional ingredients such as cordycepin, cordyceps polysaccharide, cordycepic acid, amino acid and the like, and has pharmacological activities such as tumor resistance, immunoregulation, inflammation resistance, oxidation resistance and the like.
Rosa roxburghii Tratt, also known as reeling silk flower, Senchun angelica, and Tibet fruit, is perennial deciduous shrub of Rosa of Rosaceae, and is mainly produced in southwest region of China. Roxburgh rose leaf is recorded in the herbal and wood formula for treating scabies, carbuncles and incised sores. Rosa roxburghii contains flavone, vitamin C, superoxide dismutase (SOD), polysaccharide, polyphenol, triterpenes and other components, wherein each 100 g of Rosa roxburghii contains 920 mg of flavone, 1300-3500 mg of vitamin C and 13000 units of SOD on average, and is known as 'fruit king'. Pharmacological research shows that the roxburgh rose preparation has pharmacological activities of resisting oxidation, resisting tumors, resisting atherosclerosis, reducing blood sugar and the like.
There remains a need for compositions having improved effects in lowering blood uric acid in hyperuricemia subjects.
In addition, when the natural medicine extract is used as a liquid preparation or a solid beverage for brewing, a large amount of foam is easy to appear, the aesthetic degree of the product is influenced, and the mouthfeel of the finished product is seriously influenced.
It is desirable to provide a composition having an improved effect of lowering blood uric acid in a hyperuricemic subject and having reduced foaming when used for brewing as a liquid formulation or as a solid beverage.
Disclosure of Invention
The purpose of the present invention is to provide a composition having an improved effect of reducing blood uric acid in a hyperuricemia subject.
It is a further object of the present invention to provide a composition having an improved effect of lowering blood uric acid in a hyperuricemia subject, and having reduced foam when used as a liquid formulation or as a solid beverage for brewing.
The invention relates to a uric acid-reducing composition, which comprises 1.5-2.5 parts by weight of vine tea extract and 0.5-1.5 parts by weight of cordyceps militaris extract, wherein the vine tea extract contains 30-90% by weight of dihydromyricetin, the cordyceps militaris extract contains 0.1-0.5% by weight of cordycepin, the% by weight and the parts by weight are calculated by dry weight, and the extract is obtained by taking water as an extraction solvent.
Preferably, the composition of the invention may be in the form of a liquid formulation or a solid beverage for brewing and the composition comprises a thickening agent, for example, the thickening agent may be selected from one or more of gellan gum, xanthan gum, guar gum or carrageenan, preferably gellan gum.
The invention also relates to the use of the composition in the preparation of a medicament or food product for reducing blood uric acid in a hyperuricemic subject.
The composition has an improved effect of reducing the blood uric acid of a hyperuricemia subject compared with a single ampelopsis grossedentata extract with the same dose. When the composition is used as a liquid preparation or a solid beverage for brewing, the foam is reduced, and the finished product is more attractive and more convenient to take.
Drawings
FIG. 1 is a graph showing xanthine oxidase inhibitory effect in vitro of Ampelopsis grossedentata extract;
FIG. 2 is a graph comparing the uric acid lowering effect of Ampelopsis grossedentata extract and Ampelopsis grossedentata composition on hyperuricemia population;
FIG. 3 is a graph comparing the amount of foam formed in the composition with and without the addition of a thickening agent at the same material combination ratios.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, but methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
All numerical ranges recited in this disclosure are to be understood to disclose all specific values within that range, as well as any two numerical subranges within that range. For example, with respect to 1-20, it is understood that specific values of 1, 2, 3, 3.5, 4.5, 10, 12, 15, 20, etc., and sub-ranges of 1-5, 2-6, 3.5-7.5, 15-20, etc., are disclosed.
In one aspect, the invention relates to a uric acid-reducing composition, which comprises 1.5-2.5 parts by weight of ampelopsis grossedentata extract and 0.5-1.5 parts by weight of cordyceps militaris extract, wherein the ampelopsis grossedentata extract contains 30-90% by weight of dihydromyricetin, the cordyceps militaris extract contains 0.1-0.5% by weight of cordycepin, and the extracts are obtained by using water as an extraction solvent based on dry weight.
In one aspect, the uric acid lowering composition comprises 1.8-2.2 parts by weight of ampelopsis grossedentata extract and 0.8-1.2 parts by weight of cordyceps militaris extract, wherein the ampelopsis grossedentata extract comprises 30-90% by weight of dihydromyricetin, and the cordyceps militaris extract comprises 0.1-0.5% by weight of cordycepin.
In one aspect, the uric acid-lowering composition comprises 2 parts by weight of ampelopsis grossedentata extract and 1 part by weight of cordyceps militaris extract, wherein the ampelopsis grossedentata extract comprises 30-90% by weight of dihydromyricetin, and the cordyceps militaris extract comprises 0.1-0.5% by weight of cordycepin.
In one aspect, the uric acid reducing composition further comprises 0.1-1.5 parts by weight of a roxburgh rose preparation and 0-0.5 parts by weight of a sour cherry preparation, wherein the roxburgh rose preparation comprises 5-30% by weight of vitamin C, the sour cherry preparation comprises 0.5-30% by weight of vitamin C, the% by weight and the parts by weight are calculated by dry weight, the roxburgh rose preparation is obtained by drying roxburgh rose juice, and the sour cherry preparation is obtained by drying whole sour cherry fruits.
In one aspect, the uric acid lowering composition further comprises 0.8-1.2 parts by weight of a roxburgh rose preparation and 0.1-0.2 parts by weight of a tart cherry preparation, wherein the roxburgh rose preparation comprises 5-30% by weight of vitamin C, and the tart cherry preparation comprises 5-30% by weight of vitamin C.
In one aspect, the uric acid lowering composition further comprises 1 part by weight of a roxburgh rose preparation and 0.1 part by weight of a tart cherry preparation, wherein the roxburgh rose preparation comprises 5-30% by weight of vitamin C, and the tart cherry preparation comprises 0.5-30% by weight of vitamin C.
In one aspect, the composition is in the form of a liquid formulation or a solid beverage for brewing, and the composition comprises a thickening agent.
In one aspect, the liquid formulation is an oral liquid or a liquid beverage, and the solid beverage is an effervescent tablet, a dispersible tablet, a granule or a powder.
In one aspect, the thickening agent is selected from one or more of gellan gum, xanthan gum, guar gum or carrageenan, preferably gellan gum.
In one aspect, the composition may further comprise adjuvants such as maltitol, sodium bicarbonate, sodium carbonate, sorbitol, citric acid, flavorants, juices, thickeners, and the like.
In one aspect, the composition comprises ampelopsis grossedentata extract (5-15%), cordyceps militaris extract (3-6%), rosa roxburghii preparation (1-6%), sour cherry preparation (0-3%), maltitol (5-15%), sodium bicarbonate (10-20%), sodium carbonate (2-10%), sorbitol (20-30%), citric acid (20-30%), sweetener (0-1%), edible essence (0-2%), fruit juice (0-5%) and thickener (0-5%). The composition can be prepared by the main processes of crushing, sieving, weighing, granulating, drying, mixing, tabletting and the like of the raw materials.
In one aspect, the invention relates to the use of the uric acid lowering composition of the invention in the preparation of a medicament or food for lowering blood uric acid in a hyperuricemic subject.
In one aspect, the composition is administered once daily.
In one aspect, the Ampelopsis grossedentata extract is an extract obtained using water as an extraction solvent. For example, Ampelopsis grossedentata is prepared by extracting, filtering, concentrating, drying, and sieving to obtain Ampelopsis grossedentata extract.
In one aspect, the cordyceps militaris extract is an extract obtained by using water as an extraction solvent. For example, the extract of Cordyceps militaris is prepared by extracting Cordyceps militaris with water, filtering, concentrating, drying, and sieving.
In one aspect, the Rosa roxburghii preparation is a preparation dried from Rosa roxburghii juice. For example, Rosa roxburghii can be concentrated, dried, and sieved to make Rosa roxburghii preparation.
In one aspect, the sour cherry preparation is obtained by drying and screening whole sour cherries. For example, the whole sour cherry is mixed, dried and sieved to prepare the sour cherry preparation.
In one aspect, the composition is prepared by blending the Ampelopsis grossedentata extract, the Cordyceps militaris extract, the optional Rosa roxburghii preparation, and the optional tart cherry preparation.
Examples
Example 1 in vitro xanthine oxidase inhibitory Activity of Ampelopsis grossedentata
Take XOD activity inhibition assay as an example. The in vitro XOD inhibitory activity of Ampelopsis grossedentata extract was measured as half the Inhibitory Concentration (IC)50) The specific operation is as follows:
reagent and apparatus
Reagent: the Ampelopsis grossedentata extract is prepared by extracting Ampelopsis grossedentata, filtering, concentrating, drying and sieving; xanthine oxidase (X902417-500U, 50U/mg); xanthine (X820565-25 g, not less than 99.5%, molecular weight 152); allopurinol (A800424-25 g, 98%, molecular weight 136); PBS buffer (pH7.5); hydrochloric acid solution (6 mol/L); DMSO, and the like.
The instrument comprises the following steps: a micropipette (10-100. mu.L, 100-; centrifuge tubes (1.5 mL, 15mL, 50 mL); volumetric flask (25 mL); a vortex oscillator; a constant temperature gas bath oscillator; ultraviolet spectrophotometer, etc.
Experimental methods
Solution preparation:
PBS buffer: solution A: 0.2M KH2PO 4. Precisely weighing 2.72g of the extract, and dissolving the extract in 100mL of distilled water; and B, liquid B: 0.2M Na2HPO 4. Precisely weighing 11.36g of the extract, and dissolving the extract in 400mL of distilled water; and (3) mixing the solution A: the liquid B is prepared according to the following steps of 16: 84 (56: 294) to obtain 0.2M phosphate buffer solution with pH7.5, and diluting the mixture with distilled water 2.857 times to obtain 70mM phosphate buffer solution with pH 7.5.
Xanthine oxidase solution (0.1U/mL): a40. mu.L solution of xanthine oxidase (250U/mL) at a given concentration was diluted with PBS to 10 mL, and mixed well as denoted by B (1U/mL, 10 mL), and 9 mL of PBS was added to 1mL of B and mixed well as denoted by C (0.1U/mL, 10 mL) for use.
Xanthine solution (150. mu. mol/L): accurately weighing 11.4 mg xanthine, diluting to 25mL with PBS buffer solution, performing ultrasonic treatment for 15 min, diluting 1.5mL xanthine to 30 mL, and performing ultrasonic treatment for 5 min for later use.
Hydrochloric acid solution (1 mol/L): adding a certain amount of distilled water into a high-concentration hydrochloric acid solution (6 mol/L), and diluting to 1 mol/L for later use.
Sample solutions of different concentrations: a certain amount of sample is precisely weighed, dissolved in 2% DMSO, and diluted to a corresponding concentration by PBS buffer solution for later use.
Inhibition of XOD activity assay:
negative group: 1.7 mL of LPBS buffer, 0.6 mL of xanthine oxidase solution.
Negative blank group: 2.3 mLPBS buffer.
Sample group: 1mL of sample solution, 0.7 mL of buffer solution of LPBS, and 0.6 mL of xanthine oxidase solution.
Sample blank group: 1mL of sample solution, 1.3 mL of PBS buffer.
All groups were incubated at 25 ℃ for 15 min, and 1.2 mL of xanthine solution was added and reacted at 25 ℃ for 30 min. The reaction was terminated by adding 0.5 mL of hydrochloric acid solution, and the absorbance was measured at 290 nm.
Data processing:
the XOD activity inhibition rate is calculated by the following formula:
inhibition (%) = [ ((a negative-a minus empty) - (a sample-a-like empty))/(a negative-a minus empty) ], 100%
In the formula, A negative and A negative blank are the absorbances of a negative group and a negative blank group respectively, and A sample blank are the absorbances of a sample group and a sample blank group respectively. Calculating IC according to the inhibition rate of samples with different concentrations50。
Results of the experiment
Ampelopsis grossedentata extract IC50=395.4 μ g/mL. Has a certain xanthine oxidase in vitro inhibition effect. The results are shown in FIG. 1.
Example 2 comparison of in vitro xanthine oxidase inhibitory Activity of vine tea composition compared to pure vine tea extract
The reagents, instruments and experimental methods were the same as in example 1, except that the sample combination ratios were different.
Wherein the Cordyceps militaris extract is prepared by extracting with water, filtering, concentrating, drying, and sieving; the fructus Rosae Normalis preparation is prepared by concentrating fruit juice, drying, and sieving; the sour cherry preparation is prepared by mixing, drying and screening whole sour cherries.
Different combinations of experimental samples are shown in table 1:
TABLE 1 Experimental sample combination weight ratios
The results are shown in Table 2:
TABLE 2 results of in vitro xanthine oxidase inhibitory Activity in different ratio combinations
Comparative example:
TABLE 3 results of in vitro xanthine oxidase inhibitory Activity in various ratio combinations
TABLE 4 results of in vitro xanthine oxidase inhibitory Activity in different ratio combinations
Example 3 comparison of the uric acid lowering Effect of Ampelopsis grossedentata composition in comparison with the hyperuricemia population of simply Ampelopsis grossedentata extract
The effect of taking the vine tea extract, the cordyceps militaris extract and the roxburgh rose preparation composition is compared with the effect of taking the vine tea extract alone in the hyperuricemia population. The specific information is as follows:
reagents and instrumentation:
baijie (BeneCheck) PD-G001-3-P household uric acid tester and matched test paper; roche (ROCHE) Accu-CHEK softclin household blood sampling pens. The rest of the extract or preparation sources are the same as example 2, and other common filling auxiliary materials are from commercial common raw material suppliers.
Test samples:
vine tea extract group: ampelopsis grossedentata extract and other common filling auxiliary materials
Vine tea composition group: the composition is equal to the vine tea extract in the vine tea extract group, and comprises the vine tea extract, the cordyceps militaris extract and the roxburgh rose preparation (the dry weight and the mass ratio of the three are 2: 1: 1.2)
The test population:
age: adults (18-80 years old);
quantity: ampelopsis grossedentata group (3 persons); composition set (6 persons)
Inclusion criteria were: the concentration of the fingertip blood uric acid is more than 420 mu mol/L;
evaluation indexes are as follows: blood uric acid concentration of fingertip in empty stomach state
The taking method comprises the following steps: taken after lunch
The research period is as follows: 5 weeks
Subject exclusion criteria:
1. subjects took azathioprine, aspirin (> 325 mg), atorvastatin, fenofibrate, losartan, thiazines, systemic corticosteroids, estrogens, oral contraceptives 2 weeks prior to or during the trial
2. Serum creatinine > 3.0 mg/dL
3. GPT > 100 mg/dL
4. Pregnant or lactating women
5. People who consider cancer chemotherapy or radiotherapy or other researchers to be unsuitable for taking part in test
Test procedure
Alcohol is used for disinfecting a finger area to be detected of a subject, a subsequent blood sampling point is kept to be the same finger, a blood sampling pen is penetrated by 3 grades of force, the first drop of blood is discarded, subsequent fingertip blood is taken, and the corresponding uric acid test paper is used for detecting the concentration of the fingertip blood uric acid. 8 parts per week earlier: blood was collected on an empty stomach for 5 weeks.
Results of the experiment
Subjects had a reduction in self baseline blood uric acid levels after 5 weeks of administration of the vine tea composition versus an equivalent amount of vine tea extract, as shown in table 3:
TABLE 3
After the subjects took the composition for 5 weeks, the fingertip blood uric acid level was significantly reduced compared to the initial state, while the ampelopsis grossedentata extract group had no significant change compared to the initial uric acid level. And the composition group was more significantly reduced than the ampelopsis grossedentata extract from the baseline level.
Conclusion of the experiment
The composition is more effective in reducing uric acid levels in a subject than the extract of Ampelopsis grossedentata alone. The results are shown in FIG. 2.
EXAMPLE 4 Effect of thickeners on improving foam in compositions
Apparatus and materials
The material is Ampelopsis grossedentata extract (5-15%), Cordyceps militaris extract (3-6%), Rosa roxburghii preparation (3-6%), sour cherry preparation (0-3%), maltitol (5-15%), sodium bicarbonate (10-20%), sodium carbonate (2-10%), sorbitol (20-30%), citric acid (20-30%), sweetening agent (0-1%), edible essence (0-2%) and fruit juice (0-5%). The difference between different groups is whether the thickening agent is added or not and the type of the thickening agent.
Then the solid beverage (containing effervescent tablets) is prepared by the main processes of crushing, sieving, weighing, granulating, drying, mixing, tabletting and the like of the raw materials.
Measuring cylinder, pipettor (1000 ml), constant temperature water bath, ruler.
Experimental methods
Preparing effervescent tablets added with various thickening agents of 1 percent and no thickening agent, taking 250ml of dry beakers, precisely adding 200ml of distilled water into the dry beakers respectively, keeping the water temperature at 37 ℃ for heating in a water bath, adding one piece of each beaker, measuring and recording the highest position where foam rises from the top of the liquid level, recording the height difference between the top of the liquid level and the highest position where the foam can reach, namely measuring the foaming amount, and evaluating the foaming amount through the height of the foam.
Results of the experiment
Compared with the group without the thickening agent, the foam of the group added with the thickening agent is obviously reduced, and the appearance and the taste of the product are greatly improved. The results are shown in table 4 and fig. 3.
TABLE 4 foam height Change with thickener addition
While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims (10)
1. A composition for reducing uric acid comprises 1.5-2.5 parts by weight of Ampelopsis grossedentata extract and 0.5-1.5 parts by weight of Cordyceps militaris extract, wherein the Ampelopsis grossedentata extract contains 30-90% by weight of dihydromyricetin, the Cordyceps militaris extract contains 0.1-0.5% by weight of cordycepin, the% by weight and the parts by weight are based on dry weight, and the extract is obtained by using water as an extraction solvent.
2. Uric acid lowering composition according to claim 1, wherein the uric acid lowering composition comprises 1.8-2.2 parts by weight of Ampelopsis grossedentata extract comprising 30-90% by weight of dihydromyricetin and 0.8-1.2 parts by weight of Cordyceps militaris extract comprising 0.1-0.5% by weight of cordycepin.
3. Uric acid lowering composition according to claim 1, wherein the uric acid lowering composition comprises 2 parts by weight of Ampelopsis grossedentata extract comprising 30-90% by weight of dihydromyricetin and 1 part by weight of Cordyceps militaris extract comprising 0.1-0.5% by weight of cordycepin.
4. Uric acid reducing composition according to claim 1, further comprising 0.1-1.5 parts by weight of a Rosa roxburghii preparation comprising 5-30% by weight of vitamin C and 0-0.5 parts by weight of a tart cherry preparation comprising 0.5-30% by weight of vitamin C, the% by weight and parts by weight being based on dry weight, the Rosa roxburghii preparation being obtained by drying with Rosa roxburghii juice and the tart cherry preparation being obtained by drying with whole tart cherry fruits.
5. Uric acid lowering composition according to claim 1, further comprising 0.8-1.2 parts by weight of a Rosa roxburghii preparation comprising 5-30% by weight of vitamin C and 0.1-0.2 parts by weight of a tart cherry preparation comprising 0.5-30% by weight of vitamin C.
6. Uric acid lowering composition according to claim 1, further comprising 1 part by weight of a Rosa roxburghii preparation comprising 5-30% by weight of vitamin C and 0.1 part by weight of a tart cherry preparation comprising 0.5-30% by weight of vitamin C.
7. Uric acid lowering composition according to any one of claims 1 to 6, wherein the composition is in the form of a liquid formulation or a solid beverage for brewing and comprises a thickener.
8. Uric acid lowering composition according to claim 7, wherein the liquid preparation is oral liquid or liquid beverage and the solid beverage is effervescent tablet, dispersible tablet, granule or powder.
9. Uric acid lowering composition according to claim 7, wherein the thickener is selected from one or more of gellan gum, xanthan gum, guar gum or carrageenan, preferably gellan gum.
10. Use of a uric acid lowering composition according to any one of claims 1-9 in the preparation of a medicament or food product for lowering blood uric acid in a hyperuricemic subject.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111646938.7A CN114224957A (en) | 2021-12-30 | 2021-12-30 | Composition with effect of inhibiting uric acid generation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111646938.7A CN114224957A (en) | 2021-12-30 | 2021-12-30 | Composition with effect of inhibiting uric acid generation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114224957A true CN114224957A (en) | 2022-03-25 |
Family
ID=80744556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111646938.7A Pending CN114224957A (en) | 2021-12-30 | 2021-12-30 | Composition with effect of inhibiting uric acid generation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114224957A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104473977A (en) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | Cordyceps militaris water extract as well as preparation method and application thereof |
| CN105901230A (en) * | 2016-04-27 | 2016-08-31 | 济南舒美生物科技有限公司 | Compound health tea with efficacy of hyperuricemia inhibition |
-
2021
- 2021-12-30 CN CN202111646938.7A patent/CN114224957A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104473977A (en) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | Cordyceps militaris water extract as well as preparation method and application thereof |
| CN105901230A (en) * | 2016-04-27 | 2016-08-31 | 济南舒美生物科技有限公司 | Compound health tea with efficacy of hyperuricemia inhibition |
Non-Patent Citations (3)
| Title |
|---|
| 吴淑慧等: "藤茶提取物的降尿酸作用研究", 《食品工业科技》 * |
| 禾本: "食用酸樱桃降低血液中尿酸水平", 《中国果业信息》 * |
| 郭小李: "越桔黄酮对高尿酸血症的影响"", 《中国优秀硕士学位论文全文数据库（医药卫生科技辑）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230473B (en) | Lycium ruthenicum Murr. effective extract, extracting method and extract are applied | |
| CN103702675B (en) | With lacquer tree extract of active flavonoids for increasing content and preparation method thereof | |
| CN101961375B (en) | Extractive of Pu'er tea and preparation method thereof | |
| CN105586230A (en) | Rose breezer and preparation method thereof | |
| CN108783155A (en) | A kind of sealwort, mulberry leaf, radix polygonati officinalis compatibility beverage and preparation method thereof | |
| CN106726889A (en) | The extracting method of Camellia nitidissima active ingredient and prepare the purposes of health products | |
| Famojuro | Effect of cashew apple juice (Anacardium occidentale L.) on hematology and spleen of gentamicin induced injury in albino rats | |
| Nyamien et al. | Caffeine and phenolic compounds in Cola nitida (Vent.) Schott and Endl and Garcinia kola Heckel grown in Côte d'Ivoire | |
| US20170347691A1 (en) | Method for manufacturing smilax china l. root extract having increased active ingredients and beverage composition containing the extract for detoxification | |
| Tisnadjaja et al. | Potency of cinnamomum burmannii as antioxidant and α glucosidase inhibitor and their relation to trans-cinamaldehyde and coumarin contents | |
| JP6446162B1 (en) | Hangover composition | |
| KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
| Patay et al. | Coffea arabica: a plant with rich content in caffeine | |
| CN104688933B (en) | Composition of Pu' er tea effective components and application thereof in preparing hypoglycemic drug or health food | |
| CN106578218A (en) | Method for extraction of Camellia nitidissima effective ingredients with small molecular group water and use | |
| CN108456258B (en) | Preparation method of dendrobium officinale selenium polysaccharide | |
| CN114224957A (en) | Composition with effect of inhibiting uric acid generation and preparation method thereof | |
| Sachan et al. | An investigation into phytochemical profile and neutraceutical value of amla (Emblica officinalis) fruits | |
| CN113080268A (en) | Purple tea and purple tea extract with antioxidant and/or hypoglycemic activities, and preparation method and application thereof | |
| CN102596213A (en) | Composition for counteracting smoking toxicity | |
| KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
| CN108042661A (en) | The purposes of Ramulus et Folium Mussaendae Pubescentis extract and preparation medical and health product rich in dihydromyricetin | |
| CN104911068B (en) | A kind of Taxus x media health liquor and preparation method thereof | |
| CN1943448A (en) | Bamboo juice and ginkgo drink and its producing method | |
| CN103989223B (en) | The preparation method of water chestnut beverage for dispelling alcoholic intoxication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |